Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects

The purpose of the study is to assess the effects of MOA-728 on cardiac repolarization in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Phoenix, Arizona, 85044, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Generally healthy subjects men or women aged 18-50

Exclusion criteria

Any significant clinically important disease
Family history of long QT syndrome and/or sudden cardiac death
Allergy to moxifloxacin or the quinolone class of antibiotics

Treatment and study plan

MOA-728

Drug

Primary outcomes

Cardiac repolarization will be assessed by the QTc interval in healthy subjects.

Sponsors and collaborators

Lead sponsor

Bausch Health Americas, Inc.

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo- and Moxifloxacin (Open-Label)-Controlled, 4-Period Crossover Study of the Effects of a Single Dose of MOA-728 Infused Intravenously on Cardiac Repolarization in Healthy Subjects

Important dates

Study start: 2007
Study completion: 2007
First posted: Feb 13, 2007
Registry last updated: Nov 25, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed